Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients

BACKGROUND: Procalcitonin (PCT) and C-reactive protein (CRP) were previously shown to have value for the detection of secondary infections in critically ill COVID-19 patients. However, since the introduction of immunomodulatory therapy, the value of these biomarkers is unclear. We investigated PCT a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kooistra, Emma J., van Berkel, Miranda, van Kempen, Noortje F., van Latum, Celine R. M., Bruse, Niklas, Frenzel, Tim, van den Berg, Maarten J. W., Schouten, Jeroen A., Kox, Matthijs, Pickkers, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340482/
https://www.ncbi.nlm.nih.gov/pubmed/34353339
http://dx.doi.org/10.1186/s13054-021-03717-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340482/
https://www.ncbi.nlm.nih.gov/pubmed/34353339
http://dx.doi.org/10.1186/s13054-021-03717-z

Ejemplares similares